Biotricity, Inc.BTCYNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank54
3Y CAGR-15.6%
5Y CAGR-45.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-15.6%/yr
vs +31.5%/yr prior
5Y CAGR
-45.1%/yr
Recent acceleration
Acceleration
-47.1pp
Decelerating
Percentile
P54
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 3.45% |
| Q3 2025 | -13.41% |
| Q2 2025 | 21.59% |
| Q1 2025 | 3.87% |
| Q4 2024 | 6.42% |
| Q3 2024 | 0.80% |
| Q2 2024 | -27.44% |
| Q1 2024 | 56.37% |
| Q4 2023 | -35.07% |
| Q3 2023 | -2.15% |
| Q2 2023 | 1.37% |
| Q1 2023 | -19.75% |
| Q4 2022 | 5.74% |
| Q3 2022 | 0.94% |
| Q2 2022 | 30.46% |
| Q1 2022 | -30.10% |
| Q4 2021 | 43.93% |
| Q3 2021 | 6.22% |
| Q2 2021 | 6.80% |
| Q1 2021 | -19.07% |
| Q4 2020 | 69.36% |
| Q3 2020 | -5.08% |
| Q2 2020 | -12.34% |
| Q1 2020 | 8.03% |
| Q4 2019 | 104.85% |
| Q3 2019 | 2.36% |
| Q2 2019 | -45.75% |
| Q1 2019 | -1.93% |
| Q4 2018 | 113.60% |
| Q3 2018 | -39.38% |
| Q2 2018 | -52.76% |
| Q1 2018 | 73.55% |
| Q4 2017 | -8.63% |
| Q3 2017 | 31.26% |
| Q2 2017 | 7.70% |
| Q1 2017 | -12.29% |
| Q4 2016 | 34.48% |
| Q3 2016 | -6.88% |
| Q2 2016 | 10.28% |
| Q1 2016 | -4.05% |